Navigation Links
Omeros Appoints New Vice President of Clinical Development
Date:8/5/2009

SEATTLE, Aug. 5 /PRNewswire/ -- Omeros Corporation today announced the appointment of Stephen R. Murray, M.D., Ph.D. as Vice President of Clinical Development. Dr. Murray will oversee clinical trial strategies and protocols at Omeros, and currently is leading the ongoing clinical studies for Omeros' PharmacoSurgery(TM) product candidates. These include OMS103HP, the Company's lead candidate being evaluated in a Phase 3 clinical program for improved joint function and pain reduction following arthroscopic surgery, OMS302 in a Phase 2 program for use in cataract surgery, and OMS201 in a Phase 1/2 program for use in uroendoscopy.

"Dr. Murray brings a wealth of experience in the pharmaceutical industry, having successfully directed a number of development programs in both large and small pharmaceutical companies," said Gregory A. Demopulos, M.D., Chairman & CEO of Omeros. "Dr. Murray will work closely with our team members to continue building the long-term value of Omeros and our products."

"Omeros is poised to deliver important new treatments to patients through its PharmacoSurgery platform," said Dr. Murray. "In addition, we have several preclinical central nervous system and inflammation programs that have the potential to address significant unmet medical needs. This is an important time for Omeros and I'm excited to play a role here."

Prior to Omeros, Dr. Murray served in various positions, most recently as Chief Medical Officer at Memory Pharmaceuticals, a biopharmaceutical company that developed treatments for central nervous system disorders and was acquired by Hoffman-La Roche Inc. in January 2009. Before that, Dr. Murray held various positions at Pfizer Global Pharmaceuticals, including senior medical director and therapeutic team leader for schizophrenia. Dr. Murray received his M.D. and Ph.D. in molecular and cellular biology from the Medical University of South Carolina and completed his training in psychiatry at the University of California--San Francisco. He is replacing Paul Strauss, M.D., who will continue to work with the Company on a consulting basis.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at www.omeros.com.


'/>"/>
SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
2. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
3. Omeros and BlueCrest Announce $20 Million Debt Facility
4. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
5. Omeros Appoints David A. Mann to its Board of Directors
6. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
7. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
8. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
9. Brookstone Pharmaceuticals Appoints New Corporate Position
10. PDI Appoints Gerald P. Belle as Lead Independent Director
11. Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose is a ... and error process by finding the right antidepressant faster. CNSDose speeds recovery ... relationship through a personalized approach to treatment. , A peer-reviewed and ...
(Date:5/18/2017)... Mass. (PRWEB) , ... May 18, 2017 , ... ... the procedure on April 28, 2017 at the Prince Of Wales Private Hospital. ... cervical disc at level C6-C7. The patient failed conservative treatments prior to undergoing ...
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman Carl Peck, MD , ... Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal Health, has joined ... Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior VP and General ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, is honored that Jay Crowley ... conference in Brussels, Belgium. , Crowley played a crucial role in the development ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):